news

CUPERTINO, Calif., April 22, 2015 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, April 30, 2015 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio […]

CUPERTINO, Calif., March 30, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT’s Epigenomic Regulator Program.  DUR-928 is an endogenous, small-molecule, new chemical entity (NCE) that may have broad applicability in metabolic diseases such

CUPERTINO, Calif., March 2, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2014. Total revenues were $4.3 million for the three months ended December 31, 2014 and for the three months ended December 31, 2013.  Net loss was $5.9 million for the three months ended December

Initial Phase 1 Safety Study Successfully Completed, Building on Promising Body of Preclinical Data CUPERTINO, Calif., March 2, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced its Epigenomic Regulator Program, and the successful completion of a Phase 1 clinical trial with the program’s lead product candidate DUR-928.  DUR-928 is an endogenous, small-molecule, new chemical entity

CUPERTINO, Calif., Feb. 23, 2015 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, March 2, 2015 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio

CUPERTINO, Calif., Jan. 29, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 10 at 8:00 a.m. Eastern Time.  The conference is being held at the Waldorf-Astoria Hotel in New York City.  Investors and analysts that

CUPERTINO, Calif., Dec. 16, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT’s SABER® technology to deliver an ophthalmology drug.    “We’re pleased to be working on this program

CUPERTINO, Calif., Dec. 1, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10 at 3:55 p.m. Eastern Time. The conference is being held at the Crowne Plaza Times Square Hotel in New York City. A live audio webcast

CUPERTINO, Calif., Nov. 11, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced that it has received meeting minutes from its face-to-face meeting with the FDA on September 23, 2014 regarding the POSIDUR™ program.   In the February 2014 Complete Response Letter (CRL), FDA indicated that multiple safety trials would be required to support a broad indication.  DURECT

CUPERTINO, Calif., Nov. 3, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2014.  Total revenues were $4.3 million and net loss was $7.1 million for the three months ended September 30, 2014,  compared to total revenues of $3.0 million and net loss of $6.0 million for the